...
首页> 外文期刊>Italian Journal of Anatomy and Embryology >Osteocytes signaling events induced by intermittent vs continuous Teriparatide treatment affect in vitro osteoblast differentiation and mineralization
【24h】

Osteocytes signaling events induced by intermittent vs continuous Teriparatide treatment affect in vitro osteoblast differentiation and mineralization

机译:间歇性和连续性特立帕肽治疗引起的骨细胞信号转导事件影响体外成骨细胞的分化和矿化

获取原文

摘要

PTH(1-34), also known as Teriparatide, is an active anabolic drug used in the treatment of some forms of osteoporosis and occasionally exploited to speed fracture healing. The effect of such therapies are dependent on the type of administration, in fact it has been largely demonstrated that a short administration of Teriparatide (also called intermittent) increases the bone mass, meanwhile a long administration of the same agent (known as continuous) leads to an increased resorption. The molecular reason why the type of administration is so critical for the fate of the bone remodeling is still largely unknown but it is probably due to the fact that it affects several signaling pathways and alters the biological activity of a cohort of cells: osteoblasts, lining cells, osteoclasts, and osteocytes. In the present work, we firstly focused the attention on molecular events induced by intermittent vs continuous Teriparatide treatment in a well-known osteocytes in vitro model, the MLO-Y4 cells. By the use of a gene array platform, we found many molecules upregulated or downregulated depending on the the temporal administration modes, suggesting that the drug affects in diverse manner the osteocytes related signaling pathways. In particular, we paid attention to Wisp-2, a protein of the Wnt pathway that has been demonstrated to be able to interact and influence the differentiation of osteoblasts into osteocytes and their mineralization. Secondly, through the mineralization assay, we analyzed the functional effects, involving the differentiation of osteoblast IDG-SW3 cell line, upon the conditioning culture with MLO-Y4 medium, that were pre-treated with short and long time administration of Teriparatide. These findings, consistent with the crucial role performed by osteocytes on osteoblast differentiation, clarify the molecular events downstream the short treatment with Teriparatide, suggesting that the perturbation of certain signaling patwhays, such as the Wnt pathway, is crucial for the positive regulation of bone formation.
机译:PTH(1-34),也称为Teriparatide,是一种活性的合成代谢药物,用于治疗某些形式的骨质疏松症,偶尔用于加速骨折愈合。此类疗法的效果取决于给药方式,事实上,已在很大程度上证明了短期给予特立帕肽(也称为间歇性)会增加骨量,而长期给予相同药剂(称为连续性)会导致增加吸收。施用类型对骨骼重塑的命运如此重要的分子原因仍然未知,但这可能是由于它影响了几种信号传导途径并改变了一组细胞的生物学活性:成骨细胞,内衬细胞,破骨细胞和骨细胞。在当前的工作中,我们首先将注意力集中于在著名的骨细胞体外模型MLO-Y4细胞中,间歇性或连续性特立帕肽治疗引起的分子事件。通过使用基因阵列平台,我们发现了许多分子,它们取决于时间给药模式而被上调或下调,这表明该药物以多种方式影响骨细胞相关的信号通路。特别是,我们关注Wisp-2,它是Wnt途径的一种蛋白质,已被证明能够相互作用并影响成骨细胞向骨细胞的分化及其矿化。其次,通过矿化试验,我们分析了用MLO-Y4培养基进行条件培养后,成骨细胞IDG-SW3细胞系分化的功能效果,并用特立帕肽短期和长期给药进行了预处理。这些发现与骨细胞对成骨细胞分化的关键作用相一致,阐明了特立帕肽短期治疗后的下游分子事件,表明某些信号传导通路(如Wnt通路)的扰动对于骨形成的正向调节至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号